静脉注射链杆激酶后的抗链杆激酶标位
1Department of Haematology, University Hospital, Queen's Medical Centre, Nottingham, UK.
Lancet (London, England)
|January 27, 1990
概括
为治疗心脏病发作而接受链酶的患者会产生高水平的中和抗体. 这些抗体可以在长达一年的时间内中和治疗剂量的 estreptokinase,从而影响重新治疗的决定.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 链酶是一种用于急性心肌梗塞的血栓抑制剂.
- 治疗后可以产生对链球激酶的中和抗体.
- 这些抗体对再治疗的影响是临床关注的问题.
研究的目的:
- 为了测量急性心肌梗塞治疗的患者的链球激酶中和标位.
- 评估中和抗体反应的持续时间和水平.
- 根据决定,决定是否重新注射链球酶.
主要方法:
- 在25名患者中测量了链杆激酶中和标位.
- 治疗前,治疗后3个月和治疗后4.5-8.5个月之间进行定位.
- 与治疗剂量相关的抗体水平的分析.
主要成果:
- 所有患者的治疗前标位都很低.
- 在3个月后,24名患者的标位能够中和完整的治疗剂量.
- 在4.5-8.5个月之间,20名患者中有18名患者表现出显著的中和能力.
- 8个月后的标题范围从0.4到200万单位不等.
结论:
- 患者在治疗后发展出显著的链杆激酶中和抗体.
- 这些抗体持续至少8个月,可能长达一年.
- 在8-12个月内用链球激酶重新治疗需要考虑血中和能力和剂量调整.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:22Acute Kidney Injury I: Introduction
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...